View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
June 26, 2018updated 12 Jul 2022 1:14pm

CellCentric starts Phase Ib/IIa trial of CCS1477

CellCentric has begun a Phase Ib/IIa clinical trial of CCS1477 to treat late-stage prostate cancer after receiving regulatory approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).

CellCentric has begun a Phase Ib/IIa clinical trial of CCS1477 to treat late-stage prostate cancer after receiving regulatory approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The Institute of Cancer Research in London, UK, Regius professor and The Royal Marsden NHS Foundation Trust consultant medical oncologist Johann de Bono is the chief investigator of the trial, which seeks to enrol 120 patients.

During the first-in-man trial, CCS1477’s tolerability and efficacy will be evaluated for the treatment of late-stage prostate cancer.

CCS1477 will also be tested as a monotherapy, as well as in combination with Zytiga and Xtandi at a number of sites in the UK, including Sir Bobby Robson Cancer Trials Research Centre, Newcastle and Northern Ireland Cancer Centre, Belfast.

The trial is also expected to be expended to various sites in the US, including Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia.

“Targeting both the androgen receptor and its splice variants with a novel drug such as CCS1477 could prove to be a new and exciting way to treat this disease.”

Bono said: “One of the largest areas of unmet need in prostate cancer is the growing number of men who become resistant to treatment with second-generation anti-hormonal drugs.

“Targeting both the androgen receptor and its splice variants with a novel drug such as CCS1477 could prove to be a new and exciting way to treat this disease.”

CCS1477 is a potent, selective, orally bioavailable inhibitor that features conserved bromodomains of twin histone acetyl transferase proteins, p300 and CBP.

Inhibition of p300/CBP can significantly reduce the expression of the drivers of late-stage prostate cancer; the androgen receptor (AR), AR-splice variants (AR-SV) and c-Myc.

Reducing AR-SV is said to address inherent or acquired resistance to current second generation anti-androgen treatments abiraterone (Zytiga), enzalutamide (Xtandi) and apalutamide (Erleada).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena